AstraZeneca COVID vaccine associated with rare cases of low platelets

Wednesday, June 9, 2021 (HealthDay News)

AstraZeneca COVID-19 (New Coronavirus Infection) vaccine New studies suggest that it may be associated with rare cases of low platelet levels.

Platelets are blood cells that help prevent blood loss when blood vessels are damaged. Low platelet levels may be asymptomatic, but they may increase the risk of bleeding and coagulation.

The researchers analyzed data from 5.4 million people in Scotland. This includes the 2.5 million people who first received it. COVID-19 (New Coronavirus Infection) vaccine dose.

They found that people who received the AstraZeneca vaccine had a very low risk of the following conditions: Idiopathic thrombocytopenic purpura (ITP), This is characterized by a low platelet count.

The estimated risk is 11 per million doses, Hepatitis B, influenza And MMR vaccine, 10-30 case range ITP Per million times.

Those at highest risk tended to be older (median age 69 years) and had at least one underlying chronic health problem: Heart disease, Diabetes Or chronic Kidney disease, The study has found.

Researchers have found that two weeks after vaccination with the AstraZeneca vaccine, ITP may increase slightly, potentially increasing the risk of arterial coagulation and bleeding events.

AstraZeneca vaccine is not approved for use in the United States. There was no evidence of increased risk of ITP, coagulation or bleeding with the Pfizer-BioNTech vaccine.No other COVID-19 (New Coronavirus Infection) vaccine Included in a study published online June 9 in the journal Nature medicine..

Increased risk of ITP associated with AstraZeneca vaccine Less than the risk of ITP caused by COVID-19 (New Coronavirus Infection), The researchers pointed out.

“This careful analysis of national vaccination programs, including studies of more than 2.5 million first doses. vaccineFound a slight increase in the risk of ITP, coagulation, and bleeding events after Oxford-AstraZeneca vaccination, “said Azizshake, director of the University of Edinburgh Asher Institute, co-author of the study. I am.

“This very small risk is important, but vaccine And the potentially higher risk of these consequences in developing people COVID-19 (New Coronavirus Infection)Sheikh added in a college news release.

“Reassuringly, patients vaccinated with the Pfizer-BioNTech mRNA vaccine were not found to have an overall increased risk of ITP, coagulation, and bleeding. The vaccine program has been extended to young and healthy individuals. Therefore, we plan to update the analysis. vaccine The lead author of the study, Professor Colin Simpson of Victoria University of Wellington, New Zealand, said.

For more information

The National Institutes of Health ITP.

Source: University of Edinburgh, News Release, June 9, 2021

Robert Prite

Medical news
Copyright © 2021 Health Day. all rights reserved.

Back to top button